Recent Posts
- Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
- Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
- Immix Biopharma 12 Month Review Progress Update
- Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
- Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
Recent Comments
No comments to show.